Related Experiment Video

Updated: Jul 14, 2026

Zebra II as A Novel System to Record Electrophysiological Signals in Zebrafish
06:15

Zebra II as A Novel System to Record Electrophysiological Signals in Zebrafish

Published on: August 16, 2024

The safety of amiodarone in patients with heart failure

Christian Torp-Pedersen1, Marco Metra, Philip Spark

  • 1Department of Cardiology, Bispebjerg University Hospital, Copenhagen, Denmark.

Journal of Cardiac Failure
|July 3, 2007
PubMed

Insights

Amiodarone use in heart failure patients increased the risk of death from circulatory failure. This finding was consistent across different functional classes, highlighting potential safety concerns.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • The safety and efficacy of amiodarone in heart failure management remain subjects of ongoing clinical uncertainty.
  • Chronic heart failure patients often present complex treatment challenges requiring careful drug selection.

Purpose of the Study:

  • To investigate the association between amiodarone use and mortality in patients with chronic heart failure.
  • To determine if amiodarone impacts risk of death due to specific causes like circulatory failure or sudden death.

Main Methods:

  • A randomized trial involving 3029 chronic heart failure patients comparing carvedilol and metoprolol.
  • Analysis of amiodarone use at baseline and during a median 58-month follow-up period.
  • Multivariable analysis to assess the impact of amiodarone on mortality, stratified by New York Heart Association (NYHA) functional class.

Main Results:

  • Amiodarone use was associated with a significantly increased risk of death (Hazard Ratio [HR] 1.5, P < .001).
  • The primary driver of increased mortality was death due to circulatory failure (HR 2.4, P < .001), not sudden death.
  • This elevated risk was observed consistently across NYHA Class II (HR 1.60) and NYHA Classes III + IV (HR 1.58).

Conclusions:

  • Amiodarone treatment in chronic heart failure patients is linked to a higher risk of death from circulatory failure.
  • The increased mortality risk associated with amiodarone is independent of the patient's NYHA functional class.
  • These findings underscore the need for careful consideration of amiodarone's risks in heart failure management.
Abstract

Related Concept Videos

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: &#946;-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...